Trastuzumab (anti-HER2)

Trastuzumab (anti-human HER2) is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.

Trastuzumab (anti-HER2) Chemical Structure

Click to purchase the isotype control of

39 Citations

17 Nobel Prize winners
have used Selleck products

Shimon Sakaguchi

Nature Communications 2025;16, Article number:1325

David Baker

Dev Cell 2023;58(20):2163-2180.e9.

Michael Houghton

Cell Chem Biol 2020;27(7):780-792.e5

David Julius

Cell 2017;185-198.e16

Charles M. Rice

Cell 2018;172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 10mg/ml Endotoxin Level: ＜1EU/mg

99

Specificity

Name	Citation	HER2	Others
Canertinib (CI-1033)	48	+++	EGFR
CP-724714	109	++
Sapitinib (AZD8931)	50	++++	ErbB3,EGFR
CUDC-101	23	++	EGFR,HDAC,HDAC1
Mubritinib (TAK 165)	40	++++
AEE788 (NVP-AEE788)	13	++++	EGFR,c-Abl,FLT1
AC480 (BMS-599626)	10	+	HER1,HER4
TAK-285	4	+	EGFR/HER1,HER4,MEK1
Tyrphostin AG 879	3	+	Trk
Poziotinib (NOV120101, HM781-36B)	35	++++	HER1,HER4
HER2-Inhibitor-1	1	✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Trastuzumab (anti-human HER2) is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.
Features	Human IgG1
Targets/IC₅₀/Ki	HER2
In vitro	Loss of function of CSK or PTEN confers resistance to both lapatinib and Trastuzumab in Human epidermal growth factor receptor 2 (HER2)-amplified gastric cancer (GC) cells.
Cell Research	OE19 cells transduced with CSK targeting sgRNAs or PTEN targeting sgRNAs were used for following test. OE19 cells transduced with non-targeting sgRNA as control. a Growth curve of test groups with 0.05 μM lapatinib in combination with indicated dose of Trastuzumab for 6 days.
In vivo	Trastuzumab exerts antitumor effects in ERBB2-positive AFPGC PDX models, in which statistically significant differences are present in the tumour volume between the group treated with AZD5438 combined with Trastuzumab and those treated with AZD5438 or Trastuzumab alone in ERBB2 and CCNE1 co-amplified PDX models.
Animal Research	AnimalModels:Female BALB/c nude mice of ERBB2-positive alpha-fetoprotein producing gastric carcinoma patient-derived xenograft models Dosages:10 mg/kg Administration:i.p.^[2]
References	[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366014/ [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225795/

Product Details

CAS No.	180288-69-1
Isotype	Human IgG1
Source	CHO cells
Sterility	0.2 μM filtered
Formulation	1×PBS, pH6.0
Storage	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.